{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:58:30Z","timestamp":1785333510911,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,16]]},"DOI":"10.7759\/cureus.88087","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:57:47Z","timestamp":1752677867000},"source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Calcium-Channel Blocker Use in Patients With Multiple Myeloma: A Propensity-Matched Study From the Global Federated Health Research Network"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Eidbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Malin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Festus","family":"Ibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Chierici Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504","article-title":"Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis","volume":"168","author":"Kiss S","year":"2021","unstructured":"Kiss S, Gede N, So\u00f3s A, et al.. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit Rev Oncol Hematol. 2021, 168:103504. 10.1016\/j.critrevonc.2021.103504","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00102-0","article-title":"Cancer epidemiology in the elderly","volume":"39","author":"Franceschi S","year":"2001","unstructured":"Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol. 2001, 39:219-26. 10.1016\/S1040-8428(01)00102-0","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis","volume":"104","author":"Blommestein HM","year":"2019","unstructured":"Blommestein HM, van Beurden-Tan CH, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica. 2019, 104:1026-35. 10.3324\/haematol.2018.206912","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig C","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015, 385:2197-208. 10.1016\/S0140-6736(14)60493-1","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle RA","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018, 378:241-9. 10.1056\/NEJMoa1709974","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle RA","year":"1978","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978, 64:814-26. 10.1016\/0002-9343(78)90522-3","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar MV","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016, 128:2599-606. 10.1182\/blood-2016-09-692954","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed A","year":"2014","unstructured":"Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014, 7:33-42. 10.4137\/CGM.S16817","journal-title":"Cancer Growth Metastasis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille R","year":"1989","unstructured":"Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 1989, 7:1909-14. 10.1200\/JCO.1989.7.12.1909","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40320-5_1","article-title":"MGUS and smoldering multiple myeloma: diagnosis and Epidemiology","volume":"169","author":"Mateos MV","year":"2016","unstructured":"Mateos MV, Landgren O. MGUS and smoldering multiple myeloma: diagnosis and Epidemiology. Cancer Treat Res. 2016, 169:3-12. 10.1007\/978-3-319-40320-5_1","journal-title":"Cancer Treat Res"},{"key":"ref11","article-title":"Calcium channel blocker toxicity","author":"Chakraborty RK","year":"2025","unstructured":"Chakraborty RK, Hamilton RJ. Calcium channel blocker toxicity. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013152","article-title":"Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: a systematic review and meta-analysis","volume":"97","author":"Lin Y","year":"2018","unstructured":"Lin Y, Ma L. Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e13152. 10.1097\/MD.0000000000013152","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/66.2.205","article-title":"Effect of verapamil on right ventricular pressure and atrial tachyarrhythmia after thoracotomy","volume":"66","author":"Lindgren L","year":"1991","unstructured":"Lindgren L, Lep\u00e4ntalo M, von Knorring J, Rosenberg P, Orko R, Scheinin B. Effect of verapamil on right ventricular pressure and atrial tachyarrhythmia after thoracotomy. Br J Anaesth. 1991, 66:205-11. 10.1093\/bja\/66.2.205","journal-title":"Br J Anaesth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.12.008","article-title":"Anti-anginal drugs: systematic review and clinical implications","volume":"283","author":"Pavasini R","year":"2019","unstructured":"Pavasini R, Camici PG, Crea F, et al.. Anti-anginal drugs: systematic review and clinical implications. Int J Cardiol. 2019, 283:55-63. 10.1016\/j.ijcard.2018.12.008","journal-title":"Int J Cardiol"},{"key":"ref15","article-title":"","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd Ed.  World Health Organization, Geneva, Switzerland; 2004. https:\/\/iris.who.int\/handle\/10665\/42980."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2018.07.020","article-title":"Severe hypercalcemia from multiple myeloma as an acquired cause of short QT","volume":"51","author":"Liu Y","year":"2018","unstructured":"Liu Y, P\u00e9rez-Riera AR, Barbosa-Barros R, Daminello-Raimundo R, de Abreu LC, Nikus K, Baranchuk A. Severe hypercalcemia from multiple myeloma as an acquired cause of short QT. J Electrocardiol. 2018, 51:939-40. 10.1016\/j.jelectrocard.2018.07.020","journal-title":"J Electrocardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/167125","article-title":"Pathogenesis of renal failure in multiple myeloma: any role of contrast media?","volume":"2014","author":"Mussap M","year":"2014","unstructured":"Mussap M, Merlini G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media?. Biomed Res Int. 2014, 2014:167125. 10.1155\/2014\/167125","journal-title":"Biomed Res Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90274-1","article-title":"Extreme hypercalcemia and electrocardiographic changes","volume":"54","author":"Douglas PS","year":"1984","unstructured":"Douglas PS, Carmichael KA, Palevsky PM. Extreme hypercalcemia and electrocardiographic changes. Am J Cardiol. 1984, 54:674-5. 10.1016\/0002-9149(84)90274-1","journal-title":"Am J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.57003.x","article-title":"Vasoconstriction as the etiology of hypercalcemia-induced seizures","volume":"45","author":"Chen TH","year":"2004","unstructured":"Chen TH, Huang CC, Chang YY, Chen YF, Chen WH, Lai SL. Vasoconstriction as the etiology of hypercalcemia-induced seizures. Epilepsia. 2004, 45:551-4. 10.1111\/j.0013-9580.2004.57003.x","journal-title":"Epilepsia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher EC","year":"2013","unstructured":"Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013, 8:2007-17. 10.2215\/CJN.12231212","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90481-c","article-title":"Role of calcium channel blockers in protection against experimental renal injury","volume":"90","author":"Schrier RW","year":"1991","unstructured":"Schrier RW. Role of calcium channel blockers in protection against experimental renal injury. Am J Med. 1991, 90:21S-6S. 10.1016\/0002-9343(91)90481-c","journal-title":"Am J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02153-1","article-title":"Calcium channel blocker in patients with chronic kidney disease","volume":"26","author":"Ohno S","year":"2022","unstructured":"Ohno S, Ishii A, Yanagita M, Yokoi H. Calcium channel blocker in patients with chronic kidney disease. Clin Exp Nephrol. 2022, 26:207-15. 10.1007\/s10157-021-02153-1","journal-title":"Clin Exp Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00912.x","article-title":"Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?","volume":"53","author":"Kloke HJ","year":"1998","unstructured":"Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?. Kidney Int. 1998, 53:1559-73. 10.1046\/j.1523-1755.1998.00912.x","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377364-outcomes-of-calcium-channel-blocker-use-in-patients-with-multiple-myeloma-a-propensity-matched-study-from-the-global-federated-health-research-network","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:57:48Z","timestamp":1752677868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377364-outcomes-of-calcium-channel-blocker-use-in-patients-with-multiple-myeloma-a-propensity-matched-study-from-the-global-federated-health-research-network"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.88087","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}